← Patent-cliff monitor small molecule BRIXADI BUPRENORPHINE
Loss of exclusivity July 2032 latest FDA-listed patent expiry
Drug detail Brand name BRIXADI Active ingredient BUPRENORPHINE Strength 96MG/0.27ML (356MG/ML) Dosage form SOLUTION, EXTENDED RELEASE Route SUBCUTANEOUS Modality Small molecule FDA approval May 2023 Marketing status RX
Listed patents Patent Expires Type 11135215 July 2032 product 12161640 July 2032 product 11110084 July 2032 product 10912772 July 2032 use U-3617 9937164 July 2032 product 12318379 July 2032 product 8236292 January 2027 product 8236755 July 2026 product
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.